Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding

Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate. This HIV-derived protein is used as an antigen target for vaccine development, and it is crucial that this target is stored in a buffer that reduces aggregation and enhances long-term stability. Learn how 2bind used Prometheus Panta to do a 96-condition buffer screen, find the optimal buffer for stability in standard and stressed conditions, and validate antibody binding to the antigen — all in one instrument.

Previous
How Merck KGaA uses light scattering measurements for better developability assessment of biologic therapeutics
How Merck KGaA uses light scattering measurements for better developability assessment of biologic therapeutics

Up next
Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy
Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy

Want to see more
biologics content?

Explore resources